MiMedx Group is trading 6.1% down at $4.00 ahead of its Q2 2026 earnings report scheduled for July 29, 2026.
- Investors are focused on the recovery of the company's Wound Care segment and an expected adjusted loss of $0.03 per share.
- The stock is currently trading significantly below the $6.60 average analyst price target.